肿瘤浸润性淋巴细胞在恶性血液系统疾病中的研究进展  

Research progress of tumor-infiltrating lymphocytes in malignant hematological diseases

作　　者：郑如冰 肖毅[1] Zheng Rubing;Xiao Yi(Department of Hematology,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,China)

机构地区：[1]华中科技大学同济医学院附属同济医院血液科,武汉430030

出　　处：《中华血液学杂志》2024年第6期610-614,共5页Chinese Journal of Hematology

基　　金：国家自然科学基金(82070213);湖北省知识产权局高价值知识产权培育项目(2022)。

摘　　要：近年来,免疫疗法在肿瘤治疗中进展迅速,其中免疫活性细胞的过继免疫治疗在恶性血液系统疾病的治疗中也越来越受到重视。肿瘤浸润性淋巴细胞(tumor-infiltrating lymphocyte,TIL)是一类以T细胞为主的异型淋巴细胞,具有高度异质性。作为肿瘤微环境的重要组成部分,TIL在恶性肿瘤的发生发展中至关重要。TIL是继淋巴因子激活杀伤细胞之后发现的一种新型免疫活性细胞,在不需要大量IL-2诱导的情况下即可展现出强特异性和有效性。本文就TIL的组成、特点和其在恶性血液系统疾病中的研究进展等进行综述。In recent years,immunotherapy has been progressing rapidly in tumor treatment,among which,adoptive immunotherapy of immunologically active cells has also gained increasing attention in the treatment of malignant hematological diseases.Tumor-infiltrating lymphocytes are a heterogeneous class of T-cell-based lymphocytes with high heterogeneity.As an important component of the tumor microenvironment,TILs are crucial in the development of malignant tumors.TILs are a new type of immunoreactive cells discovered after lymphokine-activated killer cells,which can show high specificity and efficacy without the need for large amounts of interleukin-2.Tumor immunotherapy with TILs has shown encouraging results and is valuable in determining patient prognosis.In this paper,we review the composition and characteristics of TILs and their progress in malignant hematologic diseases.

关 键 词：肿瘤浸润性淋巴细胞 异型淋巴细胞 恶性血液系统疾病 肿瘤微环境 免疫活性细胞 淋巴因子激活杀伤细胞 过继免疫治疗 免疫疗法 

分 类 号：R733[医药卫生—肿瘤]